These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 16896002)

  • 1. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
    Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Association of genetic polymorphisms in the DNA repair gene XPD with risk of lung and esophageal cancer in a Chinese population in Beijing].
    Xing DY; Qi J; Tan W; Miao XP; Liang G; Yu CY; Lu WF; Zhou CN; Wu M; Lin DX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Feb; 20(1):35-8. PubMed ID: 12579497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients.
    Gal TJ; Huang WY; Chen C; Hayes RB; Schwartz SM
    Laryngoscope; 2005 Dec; 115(12):2221-31. PubMed ID: 16369171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of the DNA repair genes XPD and XRCC1 and the risk of age-related macular degeneration.
    Görgün E; Güven M; Unal M; Batar B; Güven GS; Yenerel M; Tatlipinar S; Seven M; Yüksel A
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4732-7. PubMed ID: 20375340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms of DNA repair genes XPD and XRCC1 and risk of cataract development.
    Unal M; Güven M; Batar B; Ozaydin A; Sarici A; Devranoğlu K
    Exp Eye Res; 2007 Sep; 85(3):328-34. PubMed ID: 17637462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associated risk of XRCC1 and XPD cross talk and life style factors in progression of head and neck cancer in north Indian population.
    Kumar A; Pant MC; Singh HS; Khandelwal S
    Mutat Res; 2012 Jan; 729(1-2):24-34. PubMed ID: 21945240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck.
    An J; Liu Z; Hu Z; Li G; Wang LE; Sturgis EM; El-Naggar AK; Spitz MR; Wei Q
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1633-8. PubMed ID: 17684138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients.
    Chang-Claude J; Popanda O; Tan XL; Kropp S; Helmbold I; von Fournier D; Haase W; Sautter-Bihl ML; Wenz F; Schmezer P; Ambrosone CB
    Clin Cancer Res; 2005 Jul; 11(13):4802-9. PubMed ID: 16000577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.